insulet corp. - PODD
PODD
Close Chg Chg %
207.04 -2.73 -1.32%
Closed Market
204.31
-2.73 (1.32%)
Volume: 886.80K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: insulet corp. - PODD
PODD Key Data
| Open $202.93 | Day Range 202.52 - 209.32 |
| 52 Week Range 202.52 - 354.88 | Market Cap $14.38B |
| Shares Outstanding 70.40M | Public Float 70.08M |
| Beta 1.47 | Rev. Per Employee N/A |
| P/E Ratio 58.72 | EPS $3.51 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 973.49K |
PODD Performance
| 1 Week | -1.88% | ||
| 1 Month | -13.80% | ||
| 3 Months | -27.79% | ||
| 1 Year | -16.70% | ||
| 5 Years | -22.85% |
PODD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About insulet corp. - PODD
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
PODD At a Glance
Insulet Corp.
100 Nagog Park
Acton, Massachusetts 01720
| Phone | 1-978-600-7000 | Revenue | 2.71B | |
| Industry | Medical Specialties | Net Income | 247.10M | |
| Sector | Health Technology | 2025 Sales Growth | 30.725% | |
| Fiscal Year-end | 12 / 2026 | Employees | 5,400 | |
| View SEC Filings |
PODD Valuation
| P/E Current | 58.725 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 81.699 |
| Price to Sales Ratio | 7.545 |
| Price to Book Ratio | 13.205 |
| Price to Cash Flow Ratio | 35.89 |
| Enterprise Value to EBITDA | 35.302 |
| Enterprise Value to Sales | 7.651 |
| Total Debt to Enterprise Value | 0.048 |
PODD Efficiency
| Revenue/Employee | 501,500.00 |
| Income Per Employee | 45,759.259 |
| Receivables Turnover | 5.239 |
| Total Asset Turnover | 0.863 |
PODD Liquidity
| Current Ratio | 2.777 |
| Quick Ratio | 2.112 |
| Cash Ratio | 1.053 |
PODD Profitability
| Gross Margin | 72.169 |
| Operating Margin | 17.496 |
| Pretax Margin | 12.536 |
| Net Margin | 9.124 |
| Return on Assets | 7.872 |
| Return on Equity | 18.124 |
| Return on Total Capital | 9.817 |
| Return on Invested Capital | 9.80 |
PODD Capital Structure
| Total Debt to Total Equity | 66.123 |
| Total Debt to Total Capital | 39.804 |
| Total Debt to Total Assets | 31.404 |
| Long-Term Debt to Equity | 64.658 |
| Long-Term Debt to Total Capital | 38.922 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Insulet Corp. - PODD
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.31B | 1.70B | 2.07B | 2.71B | |
Sales Growth
| +18.79% | +30.02% | +22.07% | +30.73% | |
Cost of Goods Sold (COGS) incl D&A
| 419.90M | 528.80M | 611.60M | 753.70M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 63.20M | 72.80M | 99.00M | 113.10M | |
Depreciation
| 56.00M | 62.60M | 71.00M | 79.90M | |
Amortization of Intangibles
| 7.20M | 10.20M | 9.80M | 10.50M | |
COGS Growth
| +22.49% | +25.93% | +15.66% | +23.23% | |
Gross Income
| 885.40M | 1.17B | 1.46B | 1.95B | |
Gross Income Growth
| +17.12% | +31.95% | +24.97% | +33.86% | |
Gross Profit Margin
| +67.83% | +68.84% | +70.48% | +72.17% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 760.80M | 929.70M | 1.13B | 1.46B | |
Research & Development
| 180.20M | 205.00M | 219.60M | 301.10M | |
Other SG&A
| 580.60M | 724.70M | 907.40M | 1.15B | |
SGA Growth
| +22.85% | +22.20% | +21.22% | +29.16% | |
Other Operating Expense
| 87.00M | 18.60M | 24.10M | 25.00M | |
Unusual Expense
| - | - | - | 123.50M | - |
EBIT after Unusual Expense
| 37.60M | 220.00M | 308.90M | 350.30M | |
Non Operating Income/Expense
| 8.70M | 30.80M | 34.00M | 68.90M | |
Non-Operating Interest Income
| 9.80M | 28.60M | 39.50M | 34.70M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 36.50M | 36.20M | 42.70M | 79.70M | |
Interest Expense Growth
| -40.84% | -0.82% | +17.96% | +86.65% | |
Gross Interest Expense
| 37.80M | 37.80M | 44.20M | 83.90M | |
Interest Capitalized
| 1.30M | 1.60M | 1.50M | 4.20M | |
Pretax Income
| 9.80M | 214.60M | 300.20M | 339.50M | |
Pretax Income Growth
| -52.20% | +2,089.80% | +39.89% | +13.09% | |
Pretax Margin
| +0.75% | +12.65% | +14.49% | +12.54% | |
Income Tax
| 5.20M | 8.30M | (118.10M) | 92.40M | |
Income Tax - Current - Domestic
| 1.30M | 3.70M | 12.20M | 4.70M | |
Income Tax - Current - Foreign
| 4.80M | 4.10M | 6.60M | 25.40M | |
Income Tax - Deferred - Domestic
| - | 100.00K | (129.70M) | 63.80M | |
Income Tax - Deferred - Foreign
| (900.00K) | 400.00K | (7.20M) | (1.50M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 4.60M | 206.30M | 418.30M | 247.10M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 4.60M | 206.30M | 418.30M | 247.10M | |
Net Income Growth
| -72.62% | +4,384.78% | +102.76% | -40.93% | |
Net Margin Growth
| +0.35% | +12.16% | +20.19% | +9.12% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 4.60M | 206.30M | 418.30M | 247.10M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 4.60M | 206.30M | 418.30M | 247.10M | |
EPS (Basic)
| 0.0663 | 2.9577 | 5.9692 | 3.5125 | |
EPS (Basic) Growth
| -73.29% | +4,361.09% | +101.82% | -41.16% | |
Basic Shares Outstanding
| 69.38M | 69.75M | 70.08M | 70.35M | |
EPS (Diluted)
| 0.0658 | 2.943 | 5.7843 | 3.4791 | |
EPS (Diluted) Growth
| -73.14% | +4,372.64% | +96.54% | -39.85% | |
Diluted Shares Outstanding
| 69.91M | 73.63M | 73.89M | 71.89M | |
EBITDA
| 100.80M | 292.80M | 407.90M | 586.90M | |
EBITDA Growth
| -45.04% | +190.48% | +39.31% | +43.88% | |
EBITDA Margin
| +7.72% | +17.25% | +19.69% | +21.67% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 356.833 | |
| Number of Ratings | 27 | Current Quarters Estimate | 1.449 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 6.335 | |
| Last Quarter’s Earnings | 1.20 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.97 | Next Fiscal Year Estimate | 8.098 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 21 | 21 | 23 | 23 |
| Mean Estimate | 1.45 | 1.66 | 6.34 | 8.10 |
| High Estimates | 1.70 | 1.79 | 6.55 | 8.81 |
| Low Estimate | 1.26 | 1.56 | 5.89 | 7.27 |
| Coefficient of Variance | 7.25 | 3.84 | 2.11 | 3.65 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 20 | 20 | 21 |
| OVERWEIGHT | 5 | 5 | 6 |
| HOLD | 1 | 1 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Insulet Corp. - PODD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Insulet Corp. - PODD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 27, 2026 | Lisa Blair Davis SVP, Chief HR Officer | 4,617 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Prem Singh SVP, Global Operations | 7,160 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $248.12 per share | 1,776,539.20 |
| Feb 27, 2026 | Prem Singh SVP, Global Operations | 7,298 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Flavia H. Pease EVP & CFO | 9,946 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Flavia H. Pease EVP & CFO | 19,159 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Lauren Budden Group VP, CAO and Controller | 1,591 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Lauren Budden Group VP, CAO and Controller | 8,744 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $248.12 per share | 2,169,561.28 |
| Feb 27, 2026 | Lauren Budden Group VP, CAO and Controller | 8,799 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Eric Benjamin EVP and COO | 9,946 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Eric Benjamin EVP and COO | 24,512 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $248.12 per share | 6,081,917.44 |
| Feb 27, 2026 | Eric Benjamin EVP and COO | 24,907 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | John W. Kapples SVP and General Counsel | 28,382 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Lisa Blair Davis SVP, Chief HR Officer | 5,570 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Laetitia Cousin SVP, Reg, Quality & Compliance | 2,718 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Laetitia Cousin SVP, Reg, Quality & Compliance | 5,927 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $248.12 per share | 1,470,607.24 |
| Feb 27, 2026 | Laetitia Cousin SVP, Reg, Quality & Compliance | 6,038 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Prem Singh SVP, Global Operations | 5,570 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Ashley A. McEvoy President and CEO; Director | 26,143 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | Ashley A. McEvoy President and CEO; Director | 23,962 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2026 | John W. Kapples SVP and General Counsel | 4,907 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |